Despite Knowledge of Generics Benefit, Some Prefer Brand Name

Published Online: Thursday, September 13, 2012
Although many women enrolled in one state’s Medicaid program noted that generics were less expensive than brand-name medications, only half of participants preferred the cheaper drugs to their brand-name counterparts, according to the results of a study published online February 21, 2012, in Research in Social and Administrative Pharmacy.

In addition, providers, including both physicians and pharmacists, did not often discuss generic substitution, the study reported.

Researchers from the University of Tennessee, Oregon Health and Sciences University, and Ohio State University aimed to evaluate perceptions about generic medications among women enrolled in TennCare, Tennessee’s Medicaid system.

Researchers recruited 172 women of child-bearing age from primary care, gynecology, and health clinic locations, and administered a 25-item oral questionnaire on their sociodemographic background and their opinions on the efficacy, safety, cost, and preferences regarding generic and brand-name medicines.

Participants’ average age was 28.8 years (±6.4 years), and most subjects were identified as being white and married. Approximately 20% had not completed high school, the study authors stated.

Although 97.6% of participants believed that generic medications were less expensive, and 60.5% believed they were a better value than brand-name medicines, only 45.3% preferred taking the drugs, the authors found.

In addition, 23.3% believed that brand-name medications were more effective than generics, and 13.4% believed that generics caused more side effects. Only 35.5% of women reported a consultation with their pharmacist about generic drugs, and 29.7% reported a similar consultation with their physician.

Latest Articles
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Latest Issues